Incidence and Severity of COVID-19 in Relation to Anti-Receptor-Binding Domain IgG Antibody Level after COVID-19 Vaccination in Kidney Transplant Recipients.

Incidence and Severity of COVID-19 in Relation to Anti-Receptor-Binding Domain IgG Antibody Level after COVID-19 Vaccination in Kidney Transplant Recipients.

Publication date: Jan 12, 2024

Kidney transplant recipients (KTRs) elicit an impaired immune response after COVID-19 vaccination; however, the exact clinical impact remains unclear. We therefore analyse the relationship between antibody levels after vaccination and the risk of COVID-19 in a large cohort of KTRs. All KTRs living in the Netherlands were invited to send a blood sample 28 days after their second COVID-19 vaccination for measurement of their IgG antibodies against the receptor-binding domain of the SARS-CoV-2 spike protein (anti-RBD IgG). Information on COVID-19 was collected from the moment the blood sample was obtained until 6 months thereafter. Multivariable Cox and logistic regression analyses were performed to analyse which factors affected the occurrence and severity (i. e., hospitalization and/or death) of COVID-19. In total, 12,159 KTRs were approached, of whom 2885 were included in the analyses. Among those, 1578 (54. 7%) became seropositive (i. e., anti-RBD IgG level >50 BAU/mL). Seropositivity was associated with a lower risk for COVID-19, also after adjusting for multiple confounders, including socio-economic status and adherence to COVID-19 restrictions (HR 0. 37 (0. 19-0. 47), p = 0. 005). When studied on a continuous scale, we observed a log-linear relationship between antibody level and the risk for COVID-19 (HR 0. 52 (0. 31-0. 89), p = 0. 02). Similar results were found for COVID-19 severity. In conclusion, antibody level after COVID-19 vaccination is associated in a log-linear manner with the occurrence and severity of COVID-19 in KTRs. This implies that if future vaccinations are indicated, the aim should be to reach for as high an antibody level as possible and not only seropositivity to protect this vulnerable patient group from disease.

Open Access PDF

Concepts Keywords
Death COVID-19
Kidney COVID-19
Months COVID-19 vaccination
Netherlands COVID-19 Vaccines
Vaccination COVID-19 Vaccines
efficiency
Humans
Immunoglobulin G
Immunoglobulin G
Incidence
Kidney Transplantation
kidney transplantation
SARS-CoV-2
Spike Glycoprotein, Coronavirus
Spike Glycoprotein, Coronavirus
spike protein, SARS-CoV-2

Semantics

Type Source Name
disease MESH COVID-19
disease VO vaccination
disease IDO immune response
disease IDO blood
disease MESH death
drug DRUGBANK Pentaerythritol tetranitrate
disease MESH Hypertension
disease MESH Cardiovascular Disease
drug DRUGBANK Coenzyme M
disease VO efficiency
disease VO population
disease VO vaccine
disease VO vaccine effectiveness
disease MESH infection
disease IDO history
disease MESH educational level
disease VO organ
disease IDO assay
drug DRUGBANK Immune Globulin Human
drug DRUGBANK Biotin
disease MESH Clinical Progression
disease VO Glycoprotein

Original Article

(Visited 1 times, 1 visits today)